Respirology

Top Medical News
Roshini Claire Anthony, 3 hours ago

In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression 1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.

Tristan Manalac, 12 hours ago
Administrating continuous positive airway pressure (CPAP) through a helmet (h-CPAP) device safely improves oxygenation in women with moderate-to-severe acute respiratory failure (ARF) due to the coronavirus disease 2019 (COVID-19), a recent study has found.
Roshini Claire Anthony, Yesterday

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

Pearl Toh, Yesterday
The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.
Elvira Manzano, Yesterday
The US Food and Drug Administration has given the green light to Moderna and Johnson & Johnson’s COVID-19 booster shots for eligible populations amid reports of waning immunity and breakthrough infections.
Pearl Toh, 3 days ago
The investigational oral antiviral pill molnupiravir significantly slashed the risk of hospitalization or death by half in nonhospitalized adults with mild-to-moderate COVID-19, according to interim data from the phase III MOVe-OUT trial.
Elvira Manzano, 3 days ago
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Special Reports
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Roshini Claire Anthony, 31 Jul 2021

Same-day pre-event screening for SARS-CoV-2 using antigen-detecting rapid diagnostic tests (Ag-RDT) may enable the resumption of large-scale indoor events which were halted or had their attendance capacity reduced during the COVID-19 pandemic, according to a study from Spain presented at ECCMID 2021.

Elvira Manzano, 29 Jul 2021
A rapid and affordable test for diagnosing COVID-19 outside the walls of the healthcare units could improve case-finding, contact tracing, and infection control, says an expert during a pre-ECCMID 2021 session.
Pearl Toh, 29 Jul 2021
While RT-PCR is the current gold standard to confirm a SARS-CoV-2 infection, antigen rapid test (ART) for COVID-19 allows for quick detection of SARS-CoV-2 and thus fast triaging of infected patients requiring isolation at the population level, according to studies presented at ECCMID 2021.
16 Jun 2021
Ceftaroline fosamil 600 mg powder for infusion
Conference Reports
Roshini Claire Anthony, 26 Oct 2021

The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.

Pearl Toh, 26 Oct 2021
The oral selective JAK1/2 inhibitor baricitinib significantly reduces the risk of death in critically ill COVID-19 patients who are on invasive mechanical ventilation (IMV) or ECMO*, when used in combination with standard care, according to the addendum study of the COV-BARRIER trial presented at IDWeek 2021.
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
Pearl Toh, 21 Oct 2021
The monoclonal antibody (mAb) combination therapy comprising BRII-196 and BRII-198 significantly reduced the risk of hospitalization and death by more than three-quarters in non-hospitalized COVID-19 patients who were at high risk of worsening illness, according to an interim analysis of the ACTIV*-2 trial presented at IDWeek 2021.
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Roshini Claire Anthony, 18 Oct 2021

A 3-day course of remdesivir may help stave off COVID-19–related hospitalization and death, according to results of the phase III PINETREE study.